Landauer Inc

Landauer — Investor Presentation (February 2017)

24 slides from Landauer's investor presentation, Feb 10, 2017

  1. Slide 1: Investor Presentation February 2017

    LANDAUER’ Investor Presentation February 2017

  2. Slide 2: Safe Harbor Statement

    LANDAUER’ Safe Harbor Statement Some of the information shared here (including, in particular, the section titled “Fiscal Year 2017 Outlook’) constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties. These include the following, without limitat

  3. Slide 3: Compelling Investment Opportunity

    LANDAUER’ Compelling Investment Opportunity + Industry-leading technology; proprietary Optically Stimulated Lu manufacturing process yescence (OSL) crystal Global Leader in Occupational Radiation Products and Services + Installed based of over 73,000 customers; 1.8 million individuals served * 90% r

  4. Slide 4: Leading OSL Technology Supported by Proven Process

    LANDAUER’ Leading OSL Technology Supported by Proven Process Current Monthly Process (~15 million badges annually) Technology Order placed; unique s Signed for e: = “Gold standard” in accuracy Dosimetry Reports = Proprietary OSL crystal technology with results are manufactured internally made availa

  5. Slide 5: Serving Diverse End Markets Across Three Verticals

    LANDAUER’ Serving Diverse End Markets Across Three Verticals wpe A Acute Care Professional -, $149 Million in FY 2016 Revenue Hospitals Offices Industrial Estimated U.S. Market Share - Dosimetry Acute Care 74% Hospitals fF Professiona| % Offices Regional Hospitals Veterinarian Emergency Response i n

  6. Slide 6: Strong Global Footprint

    LANDAUER’ Strong Global Footprint Well-positioned to serve an expanding global customer base of ~75,000 clients @ Service Labs

  7. Slide 7: Significant International Growth Opportunity

    LANDAUER’ Significant International Growth Opportunity Estimated 25% international market share provides ample room for continued growth FY GAAP 2016 Revenue Additional $1.5 million in Equity Income from International Joint Ventures int Venture Location Nagase-LANDAUER Japan Epsilon LANDAUER Turkey

  8. Slide 8: U.S. Healthcare Trends are Fueling Opportunity

    LANDAUER’ U.S. Healthcare Trends are Fueling Opportunity New Compliance Standards Tougher State Regulations + Heightened i Diagnostic Healthcare Emerging iaaging Consolidation + Pennsylvania Requirements ; oe from The Joint Evolving + Larger buying $| Gallfornia Commission Treatments groups create +

  9. Slide 9: Uniquely Positioned to Capitalize on Demand for Solutions

    LANDAUER’ Uniquely Positioned to Capitalize on Demand for Solutions Solutions Platform Reports: Analytics: Benchmarking: Training: Continuous Necessary for Context to Relevance to peers Assures Improvement: compliance information compliance and Integrated data patient across the enterprise outcomes

  10. Slide 10: Strategic Path Forward

    LANDAUER’ Strategic Path Forward Launch and commercialization of Verifii™ platform = Intermittent analog measurement > Connected digital platform Connect: to Real Time Data Provide customers with timely, actionable compliance solutions Generate meaningful cost benefits Shift the market focus . = Sim

  11. Slide 11: Verifii: Redefining Our Core Technology

    LANDAUER’ Verifii™: Redefining Our Core Technology A truly differentiated product and platform for incremental growth wérifii = Provides customers with a scalable, digital platform that connects employees to their environment = Eliminates fragmented manual processes enabling focus on building a robu

  12. Slide 12: Creating a New Standard with Digital Dosimetry

    LANDAUER’ Creating a New Standard with Digital Dosimetry ~30 million incidents measured annually (~1% physically handled) Real-time and historic data & Data is analytics processed are and stored in 7 the cloud available to client via web& mobile app: Allows customers to track trends, monitor event s

  13. Slide 13: Significant Opportunities Across Core Verticals

    LANDAUER’ Significant Opportunities Across Core Verticals Acute Care Hospitals Professional Office Penetrate Industrial Customize = Allows customers to outsource compliance and safety solution to NDAUER at a lower cost = 74% estimated U.S. market share = Consulting force in place to meet demand from

  14. Slide 14: Balanced Approach to Capital Allocation

    LANDAUER’ Fund Competitive Dividend Investin the Business Pay Down Debt Balanced Approach to Capital Allocation Currently 2%-3% dividend yield Long history of paying competitive dividend for over 20 years Core business investments focused on top and bottom line growth = Emphasis on higher margin, an

  15. Slide 15: Compelling Investment Opportunity

    LANDAUER’ Global Leader Occupational Radiation Products and Services Increased Regulation Drives Demand Compelling Growt! and Expansion Opportunities Strong Financial G Profile Compelling Investment Opportunity Industry-leading technology; proprietary Optically Stimulated Luminescence (OSL) crystal

  16. Slide 16: Financial Overview

    LANDAUER’ Financial Overview

  17. Slide 17: LANDAUER Financial Overview

    LANDAUER’ LANDAUER Financial Overview = Approximately 90% of revenue derived from subscriptions and is recurring in Revenue ($ in millions, FYE 9/30) nature $155.1 = 2016 Revenues of $149.2 million impacted $149.7 $151.3 aa dividend, reinvestmentin the core business and capital required to support s

  18. Slide 18: Q1 FY17 Financial Highlights

    LANDAUER’ Q1 FY17 Financial Highlights Key Q1 FY 2017 Financial Drivers Revenue $40 + Revenue of $37.6 million in the first pee i we quarter of fiscal 2017 includes $35 $8 ($2.5 million) impact of our divested Medical Products business a8 ae $94 + Military product sales increased $2.2 million compar

  19. Slide 19: Q1 FY2017 and Q1 FY2016 Comparable Results

    LANDAUER’ Q1 FY2017 and Q1 FY2016 Comparable Results Qi Fv2017 (§ Millions) ORE Medical Products GU Copperas) As Reported : Excluding Divestiture* Adjustment Revenue $37.6 ge $37.6 Operating Income $74 gee $74 qi Fy2016 (§ Millions) haibamd Medical Products Eos Compara, As Reported ; Excluding Dives

  20. Slide 20: Full Year FY2016 and FY2015 Comparable Results

    LANDAUER’ Full Year FY2016 and FY2015 Comparable Results pouie Fy2016 Fy2016 Fy2016 ($ Millions) As Reported | Medical Products Radon Comparable, Excluding Adjustment Adjustment Divestitures * Revenue $149.2 $(5.8) $(0.1) $143.3 Operating Income $26.6 $(1.0) $(0.1) $25.5 Aes FY2015 FY2015 FY2015 ($

  21. Slide 21: Fiscal Year 2017 Outlook

    LANDAUER’ Fiscal Year 2017 Outlook Fiscal Year 2017 Outlook FY 2016 meee Excluding wig: | gudhen cen Divested Fiscal Year ($ Millions) . ae Businesses, Gain 2017 orind Other | onDivestiture Guidance pokes and Other sean Expenses* Revenue $149.2 ($5.9) $143.3 $149-$154 Diluted EPS $1.85 ($0.22) $1.63

  22. Slide 22: Appendix

    LANDAUER’ Appendix

  23. Slide 23: Business Facts

    LANDAUER’ Business Facts * Headquartered in Glenwood, IL * Founded in 1954 = Approximately 650 employees * 8 global markets = 73,000 annual customers served; 1.8M annual individuals served = 94%+ Customer retention rates LANDAUER at a Glance Proven Technology Platform = Industry standard OSL technol

  24. Slide 24: Use of Non-GAAP Financial Measures

    LANDAUER’ Use of Non-GAAP Financial Measures Management believes the disclosure of certain non-GAAP financial measures enhances investor understanding of our financial performance. Non-GAAP financial measures disclosed in this report include: Pro Forma Revenue and Pro Forma Operating income The Pro

Landauer — Investor Presentation (February 2017) on 6ix